The latest from Faes Farma
All the news
Faes Farma completes the acquisition of SIFI and consolidates its international leadership in ophthalmology
The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]
Faes Farma increases revenue by 12.3% to €307.4 million
The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]
Faes Farma’s Shareholders’ Meeting approves the acquisition of 100% of SIFI
Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]
Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders
The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]
Faes Farma Acquires SIFI: A Transformational Step Aligned With 2030 Ambitions and Strategy
This acquisition consolidates Faes Farma as a leader in ophthalmology, incorporating a broad portfolio in this key therapeutic area. It enhances the Group’s international expansion, facilitating direct entry into new European markets. […]
Faes Farma signs an agreement to acquire Laboratorios Edol, a leader in ophthalmology in Portugal
Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in […]
